Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02795520 · ClinicalTrials.gov registry record · Phase 1
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by OncoTherapy Science.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02795520 is a Phase 1 study that was terminated before completion, run by OncoTherapy Science. The registered enrollment target is 32 participants.
The verdict
NCT02795520, a Phase 1 study, was terminated before completion, sponsored by OncoTherapy Science.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of Phase I of this study is to test the safety and tolerability of the investigational drug, OTS167, and that of Phase II of this study is to confirm the potential response benefit of OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. In this study OTS167 will be administrated to patients with AML, ALL, advanced MDSs, advanced MPNs, or advanced CML.
Interventions
- DRUG OTS167IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-04 |
| Est. Completion | 2021-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02795520
The ClinicalTrials.gov registry entry for NCT02795520 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoTherapy Science, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OTS167IV is the first listed.
NCT02795520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02795520 about?
NCT02795520 is a clinical study titled "Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia". The purpose of Phase I of this study is to test the safety and tolerability of the investigational drug, OTS167, and that of Phase II of this study is to confirm the potential response benefit of OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitu...
What is the current status of trial NCT02795520?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-04. Estimated completion is 2021-09.
What interventions are being tested in trial NCT02795520?
The interventions under investigation include: OTS167IV (DRUG).
Who is sponsoring clinical trial NCT02795520?
This trial is sponsored by OncoTherapy Science, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.